Genpact Limited (NYSE:G) has reported record results, yet analyst sentiment remains cautious. BMO Capital's Keith Bachman has reduced the price target for Genpact from $48 to $44 while maintaining a Market Perform rating, despite acknowledging the company's strong performance.